BioTuesdays

Tag - Matthew Caufield

Opthea Logo
Markets

HCW starts Opthea at buy; PT $14

H.C. Wainwright launched coverage of Opthea (NASDAQ:OPT) with a “buy” rating and $14 price target. The stock closed at $4.97 on Dec. 7. Opthea is focused on patients suffering from retinal eye diseases, such as wet age...

December 8, 2022
Eyenovia Logo
Markets

HCW starts Eyenovia at buy; PT $12

H.C. Wainwright launched coverage of Eyenovia (NASDAQ:EYEN) with a “buy” rating and $12 price target. The stock closed at $2.15 on Oct. 4. Eyenovia is developing ophthalmic therapeutics based on the company’s microdose...

October 5, 2022
Oyster Point Pharma Logo
Markets

HCW starts Oyster Point Pharma at buy; PT $20

H.C. Wainwright launched coverage of Oyster Point Pharma (NASDAQ:OYST) with a “buy” rating and $20 price target. The stock closed at $4.43 on July 15. Oyster Point Pharma is a commercial stage biopharmaceutical company...

July 18, 2022
Gemini Therapeutics
Markets

HCW starts Gemini Therapeutics at buy; PT $20

H.C. Wainwright launched coverage of Gemini Therapeutics (NASDAQ:GMTX) with a “buy” rating and $20 price target. The stock closed at $2.43 on Dec. 14. Gemini is developing precision medicines for the treatment of...

December 15, 2021
Markets

HCW starts IVERIC Bio at buy; PT $20

H.C. Wainwright launched coverage of IVERIC Bio (NASDAQ:ISEE) with a “buy” rating and price target of $20. The stock closed at $9.07 on Aug. 18. Analyst Matthew Caufield writes that IVERIC’s retinal platform...

August 19, 2021